Centr Georges Francois Leclerc — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

2 Recruiting

6 Completed trials

1 Countries active

0 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase I

Phase I (Other)

Phase II: 3 Phase I/II: 4 Phase I: 1 Phase I (Other): 1

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

All trials

9 total

A phase 1, open-label, dose-escalation and dose-expansion study evaluating the safety, feasability and efficacy of ODI-2001 vaccine, a perso… Pending

2025-523172-23-00 Phase I 1 country
Exploratory study of the performance of dynamic PET-CT acquisition to predict 6-month morphological response in patients with hepatocellular… Pending

2026-526324-48-00 Phase I/II 1 country
PHASE IB/II CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF CHEMOIMMUNOTHERAPY PLUS SHORT COURSE OF MEK INHIBITOR IN FIRST LINE OF TREA… Recruiting

2023-508477-87-00 Phase I/II 1 country
Trial evaluating the efficacy and the safety of FOLFIRINOX3 treatment in patients with unresectable locally advanced or metastatic pancreati… Recruiting

2023-505889-29-01 Phase II 1 country
An open-label, multicentric, phase I study with expansion cohorts, evaluating the safety and the efficacy of combination of atezolizumab, ti… Ended

2024-516717-20-00 Phase I (Other) 1 country
Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human… Ended

2024-517024-20-00 Phase I/II 1 country
18F-Fluorocholine (FCH) versus 18F-Fluorodesoxyglucose (FDG) PET/CT for the detection of lesions in patients with multiple myeloma Ended

2024-516682-36-00 Phase II 1 country
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in… Ended

2024-518069-89-00 Phase II 1 country
Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in patients with colorectal cancer Ended

2024-515908-39-00 Phase I/II 1 country

Showing 1–9 of 9 trials

← All sponsors A–Z